U.S. Patent Nos.
5,688,688 (Vector for Expression of a Polypeptide in a Mammalian Cell)
Plaintiffs
Novartis Pharma AG; Novartis Vaccines and Diagnostics Inc.
Defendants
Alexion Pharmaceuticals, Inc.; Biogen IDEC, Inc.; MedImmune LLC
Status
Dismissed
BPCIA
N
U.S. Patent Nos.
7,157,276 (Use of Depth Filtration in Series with Continuous Centrifugation to Clarify Mammalian Cell Cultures) 7,759,117 (Use of Depth Filtration in Series with Continuous Centrifugation to Clarify Mammalian Cell Cultures) 8,124,350 (Methods and Products for Evaluating an Immune Response to a Therapeutic Protein) 8,318,416 (Nutrient Monitoring and Feedback Control for Increased Bioproduct Production) 8,809,049 (Methods for Producing Mammalian Cells) 8,871,449 (Methods and Products for Evaluating an Immune Response to a Therapeutic Protein) 9,005,926 (Methods of Preventing and Removing Trisulfide Bonds) 9,096,879 (Method of Supplementing Culture Media to Prevent Undesirable Amino Acid Substitutions) 9,109,015 (Method of Isolating Biomacromolecules Using Low pH and Divalent Cations) 9,212,379 (Nutrient Monitoring and Feedback Control for Increased Bioproduct Production) 9,316,641 (Assay for JC Virus Antibodies) 9,493,567 (Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab) 9,562,252 (Methods of Preventing and Removing Trisulfide Bonds) 9,696,307 (Methods for the Detection of JC Polyoma Virus) 9,709,575 (Methods and Products for Evaluating an Immune Response to a Therapeutic Protein) 9,790,533 (Methods of Preventing and Removing Trisulfide Bonds) 10,119,976 (Method of Assessing Risk of PML) 10,233,245 (Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab) 10,308,706 (Methods of Preventing and Removing Trisulfide Bonds) 10,444,234 (Assay for JC Virus Antibodies) 10,590,454 (Methods of Preventing and Removing Trisulfide Bonds) 10,677,803 (Method of Assessing Risk of PML) 10,705,095 (Methods and Products for Evaluating an Immune Response to a Therapeutic Protein) 10,844,416 (Manganese Supplementation for Control of Glycosylation in Mammalian Cell Culture Process) 11,268,119 (Copper Supplementation for Control of Glycosylation in Mammalian Cell Culture Process) 11,280,794 (Method of Assessing Risk of PML) 11,287,423 (Assay for JC Virus Antibodies) 11,292,845 (Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab)
Plaintiffs
Biogen, Inc.; Biogen MA Inc.
Defendants
Sandoz Inc.; Polpharma Biologics SA
Status
Stipulated Dismissal of U.S. Patent No. 9,109,015; Case Ongoing, Preliminary Injunction Denied
BPCIA
Y